<DOC>
	<DOCNO>NCT02016716</DOCNO>
	<brief_summary>Purpose study evaluate 2 formulation Romosozumab ( AMG785 ) Postmenopausal Women With Osteoporosis .</brief_summary>
	<brief_title>A Randomized Phase 3 Study Evaluate 2 Different Formulations Romosozumab Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Postmenopausal woman osteoporosis high risk fracture define BMD Tscore â‰¤ 2.50 lumbar spine , total hip , femoral neck AND history fragility fracture least 2 risk factor BMD T score &lt; 3.50 total hip femoral neck . History hip fracture . History metabolic bone disease ( except osteoporosis ) . Use agent affect bone metabolism . Vitamin D insufficiency . History solid organ bone marrow transplant . Hyper hypocalcemia . Hyper hypothyroidism . Hyper hypoparathyroidism .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Postmenopausal Osteoporosis</keyword>
</DOC>